BR112022016391A2 - Alvejamento mediado por aav de mirna no tratamento de distúrbios ligados a x - Google Patents

Alvejamento mediado por aav de mirna no tratamento de distúrbios ligados a x

Info

Publication number
BR112022016391A2
BR112022016391A2 BR112022016391A BR112022016391A BR112022016391A2 BR 112022016391 A2 BR112022016391 A2 BR 112022016391A2 BR 112022016391 A BR112022016391 A BR 112022016391A BR 112022016391 A BR112022016391 A BR 112022016391A BR 112022016391 A2 BR112022016391 A2 BR 112022016391A2
Authority
BR
Brazil
Prior art keywords
mirna
aav
treatment
linked disorders
mediated targeting
Prior art date
Application number
BR112022016391A
Other languages
English (en)
Inventor
Christine Meyer Kathrin
Bhatnagar Sanchita
Tushir-Singh Jogender
k kaspar Brian
Likhite Shibi
Original Assignee
Res Inst Nationwide Childrens Hospital
Univ Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Inst Nationwide Childrens Hospital, Univ Virginia Patent Foundation filed Critical Res Inst Nationwide Childrens Hospital
Publication of BR112022016391A2 publication Critical patent/BR112022016391A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

ALVEJAMENTO MEDIADO POR AAV DE MIRNA NO TRATAMENTO DE DISTÚRBIOS LIGADOS A X. A presente invenção refere-se ao alvejamento de miRNA para ativar a expressão de genes no cromossomo X inativado. Esta terapia genética é útil para o tratamento de distúrbios ligados a X, incluindo Síndrome de Rett.
BR112022016391A 2020-02-18 2021-02-18 Alvejamento mediado por aav de mirna no tratamento de distúrbios ligados a x BR112022016391A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062978285P 2020-02-18 2020-02-18
PCT/US2021/018593 WO2021168124A1 (en) 2020-02-18 2021-02-18 Aav-mediated targeting of mirna in the treatment of x-linked disorders

Publications (1)

Publication Number Publication Date
BR112022016391A2 true BR112022016391A2 (pt) 2022-10-25

Family

ID=74867685

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016391A BR112022016391A2 (pt) 2020-02-18 2021-02-18 Alvejamento mediado por aav de mirna no tratamento de distúrbios ligados a x

Country Status (10)

Country Link
US (1) US20230090989A1 (pt)
EP (1) EP4107266A1 (pt)
JP (1) JP2023513932A (pt)
KR (1) KR20220155999A (pt)
CN (1) CN115485382A (pt)
AU (1) AU2021224186A1 (pt)
BR (1) BR112022016391A2 (pt)
CA (1) CA3171959A1 (pt)
IL (1) IL295698A (pt)
WO (1) WO2021168124A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115161289B (zh) * 2022-03-14 2023-12-05 东南大学 一种用于炎症性疾病治疗的重组腺相关病毒及其构建方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
EP0733103B1 (en) 1993-11-09 2004-03-03 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
US5837484A (en) 1993-11-09 1998-11-17 Medical College Of Ohio Stable cell lines capable of expressing the adeno-associated virus replication gene
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
WO1996017947A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
AU722196B2 (en) 1995-08-30 2000-07-27 Genzyme Corporation Chromatographic purification of adenovirus and AAV
AU715543B2 (en) 1995-09-08 2000-02-03 Genzyme Corporation Improved AAV vectors for gene therapy
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
EP1696036B1 (en) 1996-09-06 2010-04-21 The Trustees of The University of Pennsylvania Use of recombinant adeno-associated virus in the manufacture of a medicament for gene therapy via muscle cells
EP2325299A3 (en) 1997-09-05 2011-10-05 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
AU2001255575B2 (en) 2000-04-28 2006-08-31 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
US6962815B2 (en) 2001-01-05 2005-11-08 Children's Hopital Inc. AAV2 vectors and methods
US9217155B2 (en) * 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
WO2013016352A1 (en) 2011-07-25 2013-01-31 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of dux4
DE102012007232B4 (de) 2012-04-07 2014-03-13 Susanne Weller Verfahren zur Herstellung von rotierenden elektrischen Maschinen
JP2015092462A (ja) 2013-09-30 2015-05-14 Tdk株式会社 正極及びそれを用いたリチウムイオン二次電池
JP6202701B2 (ja) 2014-03-21 2017-09-27 株式会社日立国際電気 基板処理装置、半導体装置の製造方法及びプログラム
JP6197169B2 (ja) 2014-09-29 2017-09-20 東芝メモリ株式会社 半導体装置の製造方法
CN108452307B (zh) * 2017-12-29 2020-07-07 中国人民解放军第四军医大学 人miRNA-493-3p的抑制剂在制备治疗肾纤维化药物中的应用
WO2019202162A1 (en) * 2018-04-20 2019-10-24 Fondazione Telethon Mir-181 inhibitors and uses thereof

Also Published As

Publication number Publication date
AU2021224186A1 (en) 2022-09-08
JP2023513932A (ja) 2023-04-04
KR20220155999A (ko) 2022-11-24
CA3171959A1 (en) 2021-08-26
EP4107266A1 (en) 2022-12-28
US20230090989A1 (en) 2023-03-23
WO2021168124A1 (en) 2021-08-26
IL295698A (en) 2022-10-01
CN115485382A (zh) 2022-12-16

Similar Documents

Publication Publication Date Title
MX2022012490A (es) Vectores de aav para la terapia genica de la retina y el snc.
BR112022016391A2 (pt) Alvejamento mediado por aav de mirna no tratamento de distúrbios ligados a x
BR112017010087A2 (pt) composições e métodos para tratar esclerose lateral amiotrófica (ela)
EA201490994A1 (ru) Функционально-модифицированные олигонуклеотиды и их субъединицы
MX2010001608A (es) Suministro mediado por aav auto-complementario de moléculas de arn interferente para tratar o evitar trastornos oculares.
MX358603B (es) Tratamiento de enfermedades relacionadas con un gen supresor de tumor mediante inhibicion del transcrito antisentido natural para el gen.
EA201892285A1 (ru) Нуклеотиды, модифицированные циклофосфонатом по положению 5'
WO2010138806A8 (en) Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
BR112022002691A2 (pt) Construtos de vesícula-aso extracelular visando stat6
WO2010151674A3 (en) Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
BR112021020515A2 (pt) Deleção mediada por vetor de aav de hotspot mutacional grande para o tratamento de distrofia muscular de duchenne
BR112021018739A8 (pt) Composições e métodos para o tratamento de doenças ou distúrbios associados a kras
WO2005123141A3 (en) Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent
WO2011097582A3 (en) Treatment of arachidonate 12-lipoxygenase, 12r type (alox12b) related diseases by inhibition of natural antisense transcript to alox12b
WO2018195360A8 (en) Therapeutic genome editing in wiskott-aldrich syndrome and x-linked thrombocytopenia
WO2020127532A3 (en) Rna encoding a protein
EP4013770A4 (en) AAV CAPSID VARIANTS FOR GENE THERAPY
BR112022006530A2 (pt) Vetores virais adenoassociados para o tratamento da doença de niemann-pick tipo c
CY1123639T1 (el) Μονοκλωνα ολιγονουκλεοτιδια για χρηση στην ιατρικη θεραπευτικη αντιμετωπιση διαταραχων του δερματος
GB201808943D0 (en) Adeno-associated iral vector-mediated gene therapy for treating frag I LE X-associated disorders
BR112023000428A2 (pt) Métodos e composições para tratar epilepsia
Zhang et al. MicroRNA-582-5p reduces propofol-induced apoptosis in developing neurons by targeting ROCK1
CA3165624A1 (en) Gene therapy for neurodegenerative disorders using polynucleotide silencing and replacement
BR112022002794A2 (pt) Terapia combinada de transgene e mirna derivado de íntron para tratamento de sca1
Fillat et al. Gene therapy for Down syndrome